home > news > detailed info

BioIVT to Host Webinar Describing In Vitro Models to Predict Herb-Drug Interactions

These in vitro models can help to identify herbal ingredients with the potential to alter the safety or efficacy of prescription drugs

BioIVT, a leading provider of biospecimens and related services, today announced that it will be hosting a webinar entitled “Whole-cell In Vitro Models Can Predict Clinically-relevant Herb-Drug Interactions (HDIs)” at 11 am ET on June 20.

“As herb-based dietary supplements continue to grow in popularity, consumers and healthcare professionals have questions related to the potential for herb-drug interactions (HDIs) that could occur in patients taking them together with medications,” said Amy Roe, PhD, DABT, senior toxicologist at The Procter & Gamble Company, and the webinar’s presenter. “But that information is difficult to determine because these products are often complex herbal mixtures with multiple ingredients.”

“It is difficult to identify HDIs because it is not always feasible to routinely conduct clinical trials and applying a deconstructionist approach to a complex mixture, using conventional in vitro methods, is less predictive of in vivo effects,” said Jonathan Jackson, PhD senior scientist, ADME-Tox at BioIVT. “We demonstrated that our model (TRANSPORTER CERTIFIED hepatocytes in sandwich culture) and approach were well suited to quantitatively assessing HDI potential providing an in vivo prediction that was remarkably in agreement with clinical observations.”

During the webinar, Dr. Roe will discuss how she collaborated with Dr. Jackson and the BioIVT team and employed this novel in vitro method to investigate clinically-relevant HDIs with Schisandra species.

Clinical studies had shown that Schisandra sphenanthera extract (SSE) reduced midazolam (MDZ) clearance in humans. In their study, Drs. Roe and Jackson showed that BioIVT’s in vitro human hepatic model accurately predicted the SSE-MDZ interaction observed in the clinic. This research has been published in Drug Metabolism and Disposition.1

Dr. Roe will also describe how sandwich-cultured human hepatocytes can be used to evaluate other herbal extracts, complex mixtures, and toxicity endpoints.

Interested parties can register for this complimentary one-hour webinar at

Reference 1. Jonathan P Jackson, Kimberly M Freeman, Weslyn W Friley, Ashley G Herman, Christopher B Black, Kenneth R Brouwer and Amy L Roe. Prediction of Clinically Relevant Herb-Drug Clearance Interactions Using a Whole Cell Approach: Schisandra sphenanthera case study. Drug Metabolism and Disposition July 11, 2017, dmd.117.075408; DOI:

About BioIVT
BioIVT, formerly BioreclamationIVT, is a leading global provider of high-quality biological specimens and value-added services. We specialize in control and disease-state samples including human and animal tissues, cell products, blood and other biofluids. Our unmatched portfolio of clinical specimens directly supports precision medicine research and the effort to improve patient outcomes by coupling comprehensive clinical data with donor samples. Our PHASEZERO® Research Services team works collaboratively with clients to provide target and biomarker validation, phenotypic assays to characterize novel therapeutics, clinical assay development and in vitro hepatic modeling solutions. And as the premier supplier of ADME-toxicology model systems, including hepatocytes and subcellular fractions, BioIVT enables scientists to better understand the pharmacokinetics and drug metabolism of newly-discovered compounds and their effects on disease processes. By combining our technical expertise, exceptional customer service, and unparalleled access to biological specimens, BioIVT serves the research community as a trusted partner in elevating science. For more information, please visit or follow the company on Twitter @BioIVT.
Print this page
Send to a friend
News and Press Releases

BioIVT to Focus on the Application of In Vitro Hepatocyte Models in Toxicology Research at the North American ISSX Meeting

BioIVT, a leading provider of research models and services for drug development, today announced that it will be participating in several sessions at the 22nd North American International Society for the Study of Xenobiotics (ISSX) Meeting. This conference will be held from July 15-19 at the Palais des congrès de Montréal in Montréal, Canada.
More info >>

White Papers

Changing Structural Landscape for Comparator Drug Supply

ADAllen Pharma

TransCelerate Biopharma is focused on advancing innovation in R&D, identifying and solving common R&D challenges and further improving patient safety, with the goal of delivering more high quality medicines to patients. In 2013, they announced its Clinical Trial Comparator Network initiative to show a mutual commitment to offer secure and rapid supply of comparator drug products. The aim of this article is to unpack the section on 'Comparator Drugs' and analyse the rationale for attempting to achieve their objectives.
More info >>

Industry Events

Synthetic Biology Congress

8-9 November 2018, London, UK

Oxford Global is proud to present its Synthetic Biology Congress taking place on 8-9 November 2018 in London. As part of our Genomics and Synthetic Biology UK series, our congress will bring together Over 600 delegates representing internationally renowned research & academic institutions, clinical research institutions and pharmaceutical companies.
More info >>

©2000-2011 Samedan Ltd.
Add to favourites

Print this page

Send to a friend
Privacy statement